


- 27 -

WHAT IS CLAIMED IS:

1. A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100Da to 800 kDa.
2. The composition of claim 1, wherein the polymer has a molecular weight no greater than 60 kDa.
3. The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. The composition of claim 1, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
5. The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. The composition of claim 1, further comprising a targeting ligand.


- 29 -

8. A method of treating an angiogenic disease comprising administering a composition of claims 1 - 7 to a mammal in need thereof.
9. The method of claim 8, wherein angiogenic disease is a solid tumor.
10. A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100 Da to 800 kDa.
11. The composition of claim 1, wherein the polymer has a molecular weight no greater than 60 kDa.
12. The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.
15. The method of claim 10, comprising the structure:



wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

16. The method of claim 15, wherein y is 5-10 and x is 90-95.
17. An HPMA-TNP-470 conjugate comprising the structure:



Wherein x is 90-95 and y is 5-10.